Mesoporous Silica Nanoparticles: Types, Synthesis, Role in the Treatment of Alzheimer’s Disease, and Other Applications
Pharmaceutics · 24.11.2023 · 15 (12) · 2666
DOI: 10.3390/pharmaceutics15122666 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Pharmaceutics, online erschienen am 24.11.2023. Verfasst von Bhagavathi Sundaram Sivamaruthi und 6 weiteren Autor:innen. Beteiligte Einrichtung: Office of Research Administration, Chiang Mai University, Chiang Mai 50200, Thailand. Die Arbeit wurde bisher 30-mal zitiert (Crossref) und nennt 120 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Fundamental Fund Research, Chiang Mai University, Chiang Mai, Thailand.
Themen: Demenz
Abstract (Originalsprache)
Globally, many individuals struggle with Alzheimer’s disease (AD), an unrelenting and incapacitating neurodegenerative condition. Despite notable research endeavors, effective remedies for AD remain constrained, prompting the exploration of innovative therapeutic avenues. Within this context, silica-based nanoplatforms have emerged with pronounced potential due to their unique attributes like expansive surface area, customizable pore dimensions, and compatibility with living systems. These nanoplatforms hold promise as prospective interventions for AD. This assessment provides a comprehensive overview encompassing various forms of mesoporous silica nanoparticles (MSNs), techniques for formulation, and their applications in biomedicine. A significant feature lies in their ability to precisely guide and control the transport of therapeutic agents to the brain, facilitated by the adaptability of these nanoplatforms as drug carriers. Their utility as tools for early detection and monitoring of AD is investigated. Challenges and prospects associated with harnessing MSNs are studied, underscoring the imperative of stringent safety evaluations and optimization of how they interact with the body. Additionally, the incorporation of multifunctional attributes like imaging and targeting components is emphasized to enhance their efficacy within the intricate milieu of AD. As the battle against the profound repercussions of AD persists, MSNs emerge as a promising avenue with the potential to propel the development of viable therapeutic interventions.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Office of Research Administration, Chiang Mai University, Chiang Mai 50200, Thailand.
- Innovation Center for Holistic Health, Nutraceuticals, and Cosmeceuticals, Faculty of Pharmacy, Chiang Mai University, Chiang Mai 50200, Thailand.
- Department of Pharmacy, Dr. Dayaram Patel Pharmacy College, Bardoli 394601, Gujarat, India.
- School of Pharmacy, Raffles University, Neemrana 301705, Rajasthan, India.
- Rajasthan Pharmacy College, Rajasthan University of Health Sciences, Jaipur 302033, Rajasthan, India.
- Department of Basic Medical Sciences, College of Medicine, AlMaarefa University, P.O. Box 71666, Riyadh 11597, Saudi Arabia.
ORCID-Profile: Bhagavathi Sundaram Sivamaruthi, Devesh U Kapoor, Mansi Gaur, Bhupendra G Prajapati, Chaiyavat Chaiyasut
Förderung
- Fundamental Fund Research, Chiang Mai University, Chiang Mai, Thailand
Zitieren
APA
Sivamaruthi, B. S., Kapoor, D. U., Kukkar, R. R., Gaur, M., Elossaily, G. M., Prajapati, B. G., & Chaiyasut, C. (2023). Mesoporous Silica Nanoparticles: Types, Synthesis, Role in the Treatment of Alzheimer’s Disease, and Other Applications. Pharmaceutics, 15(12), 2666. https://doi.org/10.3390/pharmaceutics15122666
Vancouver
Sivamaruthi BS, Kapoor DU, Kukkar RR, Gaur M, Elossaily GM, Prajapati BG, et al. Mesoporous Silica Nanoparticles: Types, Synthesis, Role in the Treatment of Alzheimer’s Disease, and Other Applications. Pharmaceutics. 2023;15(12):2666. doi:10.3390/pharmaceutics15122666
BibTeX
@article{Sivamaruthi2023,
author = {Sivamaruthi, Bhagavathi Sundaram and Kapoor, Devesh U and Kukkar, Rajiv R and Gaur, Mansi and Elossaily, Gehan M and Prajapati, Bhupendra G and Chaiyasut, Chaiyavat},
title = {Mesoporous Silica Nanoparticles: Types, Synthesis, Role in the Treatment of Alzheimer’s Disease, and Other Applications},
journal = {Pharmaceutics},
year = {2023},
volume = {15},
number = {12},
pages = {2666},
doi = {10.3390/pharmaceutics15122666}
}
EUVIMED